Mauro Panteghini

List of Publications by Year in Descending Order

298 papers	9,151 citations	49 h-index	83 g-index
325 ext. papers	10,421 ext. citations	4.8 avg, IF	6.44 L-index

#	Paper	IF	Citations
298	Glutamyltransferase reference intervals in detail.. *Liver International*, **2022**,	7.9	0
297	Lipase elevation in serum of COVID-19 patients: frequency, extent of increase and clinical value. *Clinical Chemistry and Laboratory Medicine*, **2022**, 60, 135-142	5.9	1
296	An approach for determining allowable between reagent lot variation.. *Clinical Chemistry and Laboratory Medicine*, **2022**,	5.9	6
295	Biological variation of serum cholinesterase catalytic concentrations.. *Clinical Chemistry and Laboratory Medicine*, **2022**,	5.9	0
294	Improving D-dimer testing appropriateness by controlling periodicity of retesting: prevention is better than cure.. *Clinical Chemistry and Laboratory Medicine*, **2022**,	5.9	0
293	Improving measurement uncertainty of plasma electrolytes: a complex but not impossible task. *Clinical Chemistry and Laboratory Medicine*, **2021**, 59, e129-e132	5.9	3
292	Aspartate aminotransferase in COVID-19: A probably overrated marker. *Liver International*, **2021**, 41, 2809-2810	7.9	3
291	Linking lactate dehydrogenase to the severity of COVID-19 cannot ignore the employed methodology. *American Journal of Emergency Medicine*, **2021**, 45, 652-653	2.9	2
290	Performance specifications for measurement uncertainty of common biochemical measurands according to Milan models. *Clinical Chemistry and Laboratory Medicine*, **2021**,	5.9	11
289	Automatic reflex addition of serum magnesium determination to samples with severe hypocalcemia is an effective tool to detect and treat hypomagnesemia. *Clinical Biochemistry*, **2021**, 92, 89	3.5	0
288	Use of Neurosoft expert system improves turnaround time in a laboratory section specialized in protein diagnostics: a two-year experience. *Clinical Chemistry and Laboratory Medicine*, **2021**, 59, e367-e369	5.9	0
287	Prognostic role of Krebs von den Lungen-6 (KL-6) measurement in idiopathic pulmonary fibrosis: a systematic review and meta-analysis. *Clinical Chemistry and Laboratory Medicine*, **2021**, 59, 1400-1408	5.9	3
286	Is pre-biopsy serum prostate specific antigen retesting always justified? A study of the influence of individual and analytical factors on decision making for biopsy referral. *Clinica Chimica Acta*, **2021**, 516, 77-82	6.2	2
285	Definition of Outcome-Based Prostate-Specific Antigen (PSA) Thresholds for Advanced Prostate Cancer Risk Prediction. *Cancers*, **2021**, 13,	6.6	11
284	The new multidisciplinary paradigm for fatty liver disease should also include the laboratory medicine contribution. *Liver International*, **2021**, 41, 1981-1982	7.9	
283	Serum potassium concentrations in COVID-19. *Clinica Chimica Acta*, **2021**, 512, 26-27	6.2	3
282	Verification of Harmonization of Serum Total and Free Prostate-Specific Antigen (PSA) Measurements and Implications for Medical Decisions. *Clinical Chemistry*, **2021**, 67, 543-553	5.5	15

281	Serum Prostate-Specific Antigen Testing for Early Detection of Prostate Cancer: Managing the Gap between Clinical and Laboratory Practice. *Clinical Chemistry*, **2021**, 67, 602-609	5.5	8
280	Impact of optimizing pre-analytical phase on the diagnosis of gestational diabetes and related outcomes. *Clinical Chemistry and Laboratory Medicine*, **2021**, 59, 1981-1987	5.9	0
279	Prospective validation of an automatic reflex test for identifying spurious elevations of mean corpuscular haemoglobin concentration due to the presence of cold agglutinins. *Scandinavian Journal of Clinical and Laboratory Investigation*, **2021**, 81, 598-600	2	2
278	Pancreatic lipase: why laboratory community does not take enough care of this clinically important test?. *Clinical Chemistry and Laboratory Medicine*, **2021**, 59, 1914-1920	5.9	2
277	Novel Criteria for the Observe-Zone of the ESC 0/1h-hs-cTnT Algorithm. *Circulation*, **2021**, 144, 773-787	16.7	2
276	Letter to the Editor: Serum Albumin in COVID-19: A Good Example in Which Analytical and Clinical Performance of a Laboratory Test Are Strictly Intertwined. *Hepatology*, **2021**, 74, 2905-2907	11.2	4
275	Impact of managing affected results in haemolysed samples of an infant-maternity hospital using an unconventional approach. *Clinical Biochemistry*, **2021**, 95, 49-53	3.5	
274	Improving the laboratory result release process in the light of ISO 15189:2012 standard. *Clinica Chimica Acta*, **2021**, 522, 167-173	6.2	2
273	Anti-tumour necrosis factor antibodies and circulating lymphocyte phenotypes in inflammatory bowel disease. *International Immunopharmacology*, **2021**, 100, 108081	5.8	
272	Sources and clinical significance of aspartate aminotransferase increases in COVID-19. *Clinica Chimica Acta*, **2021**, 522, 88-95	6.2	5
271	Optimizing Available Tools for Achieving Result Standardization: Value Added by Joint Committee on Traceability in Laboratory Medicine (JCTLM). *Clinical Chemistry*, **2021**, 67, 1590-1605	5.5	3
270	Further improvement of the quality of tube transportation system is needed to prevent 'seasonal' pseudohyperkalaemia. *Clinica Chimica Acta*, **2020**, 510, 644-646	6.2	0
269	Measurement of Serum Neuron-Specific Enolase in Neuroblastoma: Is There a Clinical Role?. *Clinical Chemistry*, **2020**, 66, 667-675	5.5	9
268	IFCC Working Group Recommendations for Correction of Bias Caused by Noncommutability of a Certified Reference Material Used in the Calibration Hierarchy of an End-User Measurement Procedure. *Clinical Chemistry*, **2020**, 66, 769-778	5.5	12
267	Implementation of metrological traceability in laboratory medicine: where we are and what is missing. *Clinical Chemistry and Laboratory Medicine*, **2020**, 58, 1200-1204	5.9	15
266	Laboratory-related issues in the measurement of cardiac troponins with highly sensitive assays. *Clinical Chemistry and Laboratory Medicine*, **2020**, 58, 1773-1783	5.9	7
265	The utility of measurement uncertainty in medical laboratories. *Clinical Chemistry and Laboratory Medicine*, **2020**, 58, 1407-1413	5.9	26
264	A Comprehensive Appraisal of Laboratory Biochemistry Tests as Major Predictors of COVID-19 Severity. *Archives of Pathology and Laboratory Medicine*, **2020**, 144, 1457-1464	5	37

263	Trueness evaluation and verification of inter-assay agreement of serum folate measuring systems. *Clinical Chemistry and Laboratory Medicine*, **2020**, 58, 1697-1705	5.9	3
262	Traceability validation of six enzyme measurements on the Abbott Alinity c analytical system. *Clinical Chemistry and Laboratory Medicine*, **2020**, 58, 1250-1256	5.9	11
261	The internal quality control in the traceability era. *Clinical Chemistry and Laboratory Medicine*, **2020**, 59, 291-300	5.9	11
260	Derivation of performance specifications for uncertainty of serum C-reactive protein measurement according to the Milan model 3 (state of the art). *Clinical Chemistry and Laboratory Medicine*, **2020**, 58, e263-e265	5.9	8
259	Hypoalbuminemia and elevated D-dimer in COVID-19 patients: a call for result harmonization. *Clinical Chemistry and Laboratory Medicine*, **2020**, 58, e255-e256	5.9	14
258	Lactate dehydrogenase: an old enzyme reborn as a COVID-19 marker (and not only). *Clinical Chemistry and Laboratory Medicine*, **2020**, 58, 1979-1981	5.9	9
257	Searching for a role of procalcitonin determination in COVID-19: a study on a selected cohort of hospitalized patients. *Clinical Chemistry and Laboratory Medicine*, **2020**, 59, 433-440	5.9	7
256	Highly sensitive troponin T measurement after pneumatic tube transportation: The sample type can make the difference. *Clinica Chimica Acta*, **2020**, 503, 231-232	6.2	
255	Daily monitoring of a control material with a concentration near the limit of detection improves the measurement accuracy of highly sensitive troponin assays. *Clinical Chemistry and Laboratory Medicine*, **2020**, 58, e29-e31	5.9	5
254	Validation and verification of examination procedures in medical laboratories: opinion of the EFLM Working Group Accreditation and ISO/CEN standards (WG-A/ISO) on dealing with ISO 15189:2012 demands for method verification and validation. *Clinical Chemistry and Laboratory Medicine*, **2020**, 58, 361-367	5.9	6
253	Definition of analytical quality specifications for serum total folate measurements using a simulation outcome-based model. *Clinical Chemistry and Laboratory Medicine*, **2020**, 58, e66-e68	5.9	5
252	Biological variation of two serum markers for preeclampsia prediction. *Clinical Chemistry and Laboratory Medicine*, **2020**, 58, e27-e28	5.9	1
251	Reflex Testing of Free Prostate-Specific Antigen as Effective Health Care Policy. *Archives of Pathology and Laboratory Medicine*, **2019**, 143, 1045	5	2
250	Defining the plasma folate concentration for optimal neural tube defects prevention cannot ignore the impact of the employed methodology. *American Journal of Clinical Nutrition*, **2019**, 110, 780-781	7	4
249	Clinical Governance Should Be a Priority When Care Delivery Systems Are Disrupted. *Archives of Pathology and Laboratory Medicine*, **2019**, 143, 1046	5	1
248	Procalcitonin: Between evidence and critical issues. *Clinica Chimica Acta*, **2019**, 496, 7-12	6.2	23
247	Commutability of reference and control materials: an essential factor for assuring the quality of measurements in Laboratory Medicine. *Clinical Chemistry and Laboratory Medicine*, **2019**, 57, 967-973	5.9	17
246	Impact of total automation consolidating first-line laboratory tests on diagnostic blood loss. *Clinical Chemistry and Laboratory Medicine*, **2019**, 57, 1721-1729	5.9	1

245	Clinical Governance Remains a Priority in Total Laboratory Automation Era. *journal of applied laboratory medicine, The*, **2019**, 4, 130-132	2	5
244	Analytical validation of a highly sensitive point-of-care system for cardiac troponin I determination. *Clinical Chemistry and Laboratory Medicine*, **2019**, 58, 138-145	5.9	9
243	Symptoms Predictive of Acute Myocardial Infarction in the Troponin Era: Analysis From the TRAPID-AMI Study. *Critical Pathways in Cardiology*, **2019**, 18, 10-15	1.3	4
242	Documenting metrological traceability as intended by ISO 15189:2012: A consensus statement about the practice of the implementation and auditing of this norm element. *Clinical Chemistry and Laboratory Medicine*, **2019**, 57, 459-464	5.9	8
241	Making new biomarkers a reality: the case of serum human epididymis protein 4. *Clinical Chemistry and Laboratory Medicine*, **2019**, 57, 1284-1294	5.9	14
240	A study of biological and lifestyle factors, including within-subject variation, affecting concentrations of growth differentiation factor 15 in serum. *Clinical Chemistry and Laboratory Medicine*, **2019**, 57, 1035-1043	5.9	8
239	Letter to the Editor: Establishing Reliable Pediatric Percentiles of Serum Liver Enzyme Concentrations Cannot Ignore the Employed Methodology. *Hepatology*, **2019**, 69, 1361-1362	11.2	1
238	Trueness Evaluation and Verification of Interassay Agreement of 11 Serum IgA Measuring Systems: Implications for Medical Decisions. *Clinical Chemistry*, **2019**, 65, 473-483	5.5	5
237	Combined testing of copeptin and high-sensitivity cardiac troponin T at presentation in comparison to other algorithms for rapid rule-out of acute myocardial infarction. *International Journal of Cardiology*, **2019**, 276, 261-267	3.2	13
236	Suppressing all test results in grossly hemolyzed samples: is this approach appropriate in every case?. *Clinical Chemistry and Laboratory Medicine*, **2019**, 57, e118-e120	5.9	2
235	Serum Fetoprotein in pediatric oncology: not a children's tale. *Clinical Chemistry and Laboratory Medicine*, **2019**, 57, 783-797	5.9	14
234	Reply to "Analytical performance assessment of a novel cartridge-based blood gas analyzer". *Clinical Biochemistry*, **2019**, 63, 156-157	3.5	1
233	Plasma midregional proadrenomedullin (MR-proADM) concentrations and their biological determinants in a reference population. *Clinical Chemistry and Laboratory Medicine*, **2018**, 56, 1161-1168	5.9	11
232	The role of external quality assessment in the verification of in vitro medical diagnostics in the traceability era. *Clinical Biochemistry*, **2018**, 57, 23-28	3.5	16
231	Measurement uncertainty: Friend or foe?. *Clinical Biochemistry*, **2018**, 57, 3-6	3.5	14
230	Random uncertainty of photometric determination of hemolysis index on the Abbott Architect c16000 platform. *Clinical Biochemistry*, **2018**, 57, 62-64	3.5	13
229	IFCC Working Group Recommendations for Assessing Commutability Part 1: General Experimental Design. *Clinical Chemistry*, **2018**, 64, 447-454	5.5	64
228	IFCC Working Group Recommendations for Assessing Commutability Part 2: Using the Difference in Bias between a Reference Material and Clinical Samples. *Clinical Chemistry*, **2018**, 64, 455-464	5.5	57

227	IFCC Working Group Recommendations for Assessing Commutability Part 3: Using the Calibration Effectiveness of a Reference Material. *Clinical Chemistry*, **2018**, 64, 465-474	5.5	29
226	Traceability of alkaline phosphatase measurement may also vary considerably using the same analytical system: the case of Abbott Architect. *Clinical Chemistry and Laboratory Medicine*, **2018**, 56, e135-e137	5.9	4
225	Defining permissible limits for the combined uncertainty budget in the implementation of metrological traceability. *Clinical Biochemistry*, **2018**, 57, 7-11	3.5	15
224	Offering Aspartate Aminotransferase as a Reflex Test: An Easy but Effective Way to Improve Appropriateness of Laboratory Requests. *American Journal of Clinical Pathology*, **2018**, 149, 456-457	1.9	3
223	Laboratory testing in the emergency department: an Italian Society of Clinical Biochemistry and Clinical Molecular Biology (SIBioC) and Academy of Emergency Medicine and Care (AcEMC) consensus report. *Clinical Chemistry and Laboratory Medicine*, **2018**, 56, 1655-1659	5.9	10
222	Human Chorionic Gonadotropin Assays for Testicular Tumors: Closing the Gap between Clinical and Laboratory Practice. *Clinical Chemistry*, **2018**, 64, 270-278	5.5	16
221	Serum human epididymis protein 4 vs. carbohydrate antigen 125 in ovarian cancer follow-up. *Clinical Biochemistry*, **2018**, 60, 84-90	3.5	10
220	Novel generations of laboratory instruments should not worsen analytical quality: The case of GEM Premier 5000. *Clinical Biochemistry*, **2018**, 58, 128-130	3.5	3
219	Different calibrator options may strongly influence the trueness of serum transferrin measured by Abbott Architect systems. *Clinica Chimica Acta*, **2018**, 477, 119-120	6.2	2
218	Reply to: Hyperuricemia does not seem to be an independent risk factor for coronary heart disease. *Clinical Chemistry and Laboratory Medicine*, **2018**, 56, e63-e64	5.9	1
217	Impact of age on the performance of the ESC 0/1h-algorithms for early diagnosis of myocardial infarction. *European Heart Journal*, **2018**, 39, 3780-3794	9.5	43
216	Implementation of an internal quality control programme for the photometric determination of icteric index. *Journal of Clinical Pathology*, **2018**, 71, 851-852	3.9	2
215	The role of laboratory in ensuring appropriate test requests. *Clinical Biochemistry*, **2017**, 50, 555-561	3.5	28
214	Pre-analytical and analytical aspects affecting clinical reliability of plasma glucose results. *Clinical Biochemistry*, **2017**, 50, 587-594	3.5	21
213	Evaluation of long-term imprecision of automated complete blood cell count on the Sysmex XN-9000 system. *Clinical Chemistry and Laboratory Medicine*, **2017**, 55, e219-e222	5.9	9
212	Serial Sampling of High-Sensitivity Cardiac Troponin T May Not Be Required for Prediction of Acute Myocardial Infarction Diagnosis in Chest Pain Patients with Highly Abnormal Concentrations at Presentation. *Clinical Chemistry*, **2017**, 63, 542-551	5.5	26
211	Prognostic Utility of a Modified HEART Score in Chest Pain Patients in the Emergency Department. *Circulation: Cardiovascular Quality and Outcomes*, **2017**, 10,	5.8	48
210	Tackling serum folate test in European countries within the health technology assessment paradigm: request appropriateness, assays and health outcomes. *Clinical Chemistry and Laboratory Medicine*, **2017**, 55, 1262-1275	5.9	10

209	American Liver Guidelines and Cutoffs for "Normal" ALT: A Potential for Overdiagnosis. *Clinical Chemistry*, **2017**, 63, 1196-1198	5.5	16
208	High sensitivity cardiac troponin T in patients not having an acute coronary syndrome: results from the TRAPID-AMI study. *Biomarkers*, **2017**, 22, 709-714	2.6	6
207	Analytical performance specifications for external quality assessment - definitions and descriptions. *Clinical Chemistry and Laboratory Medicine*, **2017**, 55, 949-955	5.9	31
206	Total laboratory automation: Do stat tests still matter?. *Clinical Biochemistry*, **2017**, 50, 605-611	3.5	39
205	Establishing reference intervals for galectin-3 concentrations in serum requires careful consideration of its biological determinants. *Clinical Biochemistry*, **2017**, 50, 599-604	3.5	9
204	Fast track protocols using highly sensitive troponin assays for ruling out and ruling in non-ST elevation acute coronary syndrome. *Clinical Chemistry and Laboratory Medicine*, **2017**, 55, 1683-1689	5.9	10
203	Strategies to define performance specifications in laboratory medicine: 3 years on from the Milan Strategic Conference. *Clinical Chemistry and Laboratory Medicine*, **2017**, 55, 1849-1856	5.9	33
202	Laboratory testing in the emergency department: An Italian Society of Clinical Biochemistry and Clinical Molecular Biology (SIBioC) and Academy of Emergency Medicine and Care (AcEMC) consensus report. *Emergency Care Journal*, **2017**, 13,	1.2	2
201	Defining a roadmap for harmonizing quality indicators in Laboratory Medicine: a consensus statement on behalf of the IFCC Working Group "Laboratory Error and Patient Safety" and EFLM Task and Finish Group "Performance specifications for the extra-analytical phases". *Clinical Chemistry and Laboratory Medicine*, **2017**, 55, 1478-1488	5.9	47
200	Evaluation of the trueness of serum alkaline phosphatase measurement in a group of Italian laboratories. *Clinical Chemistry and Laboratory Medicine*, **2017**, 55, e47-e50	5.9	14
199	Progress and impact of enzyme measurement standardization. *Clinical Chemistry and Laboratory Medicine*, **2017**, 55, 334-340	5.9	30
198	Clinical impact of glycolysis inhibition on plasma glucose results requires caution. *Annals of Clinical Biochemistry*, **2017**, 54, 302-303	2.2	4
197	Criteria for assigning laboratory measurands to models for analytical performance specifications defined in the 1st EFLM Strategic Conference. *Clinical Chemistry and Laboratory Medicine*, **2017**, 55, 189-194	5.9	87
196	A Summary of Worldwide National Activities in Chronic Kidney Disease (CKD) Testing. *Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine*, **2017**, 28, 302-314	2.4	2
195	Hyperuricemia as risk factor for coronary heart disease incidence and mortality in the general population: a systematic review and meta-analysis. *Clinical Chemistry and Laboratory Medicine*, **2016** , 54, 7-15	5.9	93
194	Cystatin C provides a better estimate of the effect of glomerular filtration rate on serum human epididymis protein 4 concentrations. *Clinical Chemistry and Laboratory Medicine*, **2016**, 54, 1629-34	5.9	6
193	Multicenter Evaluation of a 0-Hour/1-Hour Algorithm in the Diagnosis of Myocardial Infarction With High-Sensitivity Cardiac Troponin T. *Annals of Emergency Medicine*, **2016**, 68, 76-87.e4	2.1	214
192	Laboratory medicine in the new healthcare environment. *Clinical Chemistry and Laboratory Medicine* , **2016**, 54, 523-33	5.9	35

191	More on the accuracy of the Architect enzymatic assay for hemoglobin A1c and its traceability to the IFCC reference system. *Clinical Chemistry and Laboratory Medicine*, **2016**, 54, e71-3	5.9	5
190	Generation of data on within-subject biological variation in laboratory medicine: An update. *Critical Reviews in Clinical Laboratory Sciences*, **2016**, 53, 313-25	9.4	59
189	Diagnostic and prognostic implications using age- and gender-specific cut-offs for high-sensitivity cardiac troponin T - Sub-analysis from the TRAPID-AMI study. *International Journal of Cardiology*, **2016**, 209, 26-33	3.2	78
188	Frequency of Pancreatic Hyperamylasemia in Human Immunodeficiency Virus-Positive Patients in the Highly Active Antiretroviral Therapy Era. *American Journal of Clinical Pathology*, **2016**, 145, 128-33	1.9	3
187	Heparinate but not serum tubes are susceptible to hemolysis by pneumatic tube transportation. *Clinical Chemistry and Laboratory Medicine*, **2016**, 54, 785-9	5.9	10
186	The Use of Very Low Concentrations of High-sensitivity Troponin T to Rule Out Acute Myocardial Infarction Using a Single Blood Test. *Academic Emergency Medicine*, **2016**, 23, 1004-13	3.4	53
185	Are blood ammonia concentrations dependent on □-glutamyl-transferase levels in plasma?. *Journal of Clinical Pathology*, **2016**, 69, 551-2	3.9	3
184	Verification of the harmonization of human epididymis protein 4 assays. *Clinical Chemistry and Laboratory Medicine*, **2016**, 54, 1635-43	5.9	13
183	Optimal collection tubes for plasma glucose determination: confusion reigns supreme. *Clinical Chemistry and Laboratory Medicine*, **2016**, 54, e281-3	5.9	4
182	Reference intervals for the Kryptor second-generation chromogranin A assay. *Clinical Chemistry and Laboratory Medicine*, **2016**, 54, e335-e337	5.9	3
181	Colour coding for blood collection tube closures - a call for harmonisation. *Clinical Chemistry and Laboratory Medicine*, **2015**, 53, 371-6	5.9	19
180	Preanalytical quality improvement. In pursuit of harmony, on behalf of European Federation for Clinical Chemistry and Laboratory Medicine (EFLM) Working group for Preanalytical Phase (WG-PRE). *Clinical Chemistry and Laboratory Medicine*, **2015**, 53, 357-70	5.9	83
179	Defining analytical performance specifications: Consensus Statement from the 1st Strategic Conference of the European Federation of Clinical Chemistry and Laboratory Medicine. *Clinical Chemistry and Laboratory Medicine*, **2015**, 53, 833-5	5.9	274
178	Laboratory medicine as the science that underpins medicine: the "high-sensitivity" troponin paradigm. *Clinical Chemistry and Laboratory Medicine*, **2015**, 53, 653-64	5.9	11
177	A new robust statistical model for interpretation of differences in serial test results from an individual. *Clinical Chemistry and Laboratory Medicine*, **2015**, 53, 815-22	5.9	8
176	Tumor Marker Ordering: Do Not Lose Control: A Prospective Clinical Trial. *American Journal of Clinical Pathology*, **2015**, 144, 649-58	1.9	12
175	The calibrator value assignment protocol of the Abbott enzymatic creatinine assay is inadequate for ensuring suitable quality of serum measurements. *Clinica Chimica Acta*, **2015**, 450, 125-6	6.2	14
174	Human epididymis protein 4: factors of variation. *Clinica Chimica Acta*, **2015**, 438, 171-7	6.2	31

173	Role and Responsibilities of Laboratory Medicine Specialists in the Verification OF Metrological Traceability of Medical Diagnostics. *Journal of Medical Biochemistry*, **2015**, 34, 282-287	1.9	21
172	Body mass index does not influence human epididymis protein 4 concentrations in serum. *Clinica Chimica Acta*, **2015**, 446, 163-4	6.2	8
171	Evaluation of standardization capability of current cardiac troponin I assays by a correlation study: results of an IFCC pilot project. *Clinical Chemistry and Laboratory Medicine*, **2015**, 53, 677-90	5.9	25
170	Performance criteria for combined uncertainty budget in the implementation of metrological traceability. *Clinical Chemistry and Laboratory Medicine*, **2015**, 53, 905-12	5.9	40
169	How to assess the quality of your analytical method?. *Clinical Chemistry and Laboratory Medicine*, **2015**, 53, 1707-18	5.9	34
168	Troponin T measured with highly sensitive assay (hsTnT) on admission does not reflect infarct size in ST-elevation myocardial infarction patients receiving primary percutaneous coronary intervention. *Clinical Chemistry and Laboratory Medicine*, **2015**, 53, e173-4	5.9	0
167	Soluble transferrin receptor in complicated anemia. *Clinica Chimica Acta*, **2014**, 431, 143-7	6.2	29
166	Evaluation of the impact of standardization process on the quality of serum creatinine determination in Italian laboratories. *Clinica Chimica Acta*, **2014**, 427, 100-6	6.2	27
165	Promoting clinical and laboratory interaction by harmonization. *Clinica Chimica Acta*, **2014**, 432, 15-21	6.2	48
164	Harmonization of laboratory testing - Current achievements and future strategies. *Clinica Chimica Acta*, **2014**, 432, 4-7	6.2	43
163	Tracing a roadmap for vitamin B12 testing using the health technology assessment approach. *Clinical Chemistry and Laboratory Medicine*, **2014**, 52, 767-77	5.9	4
162	Is serum human epididymis protein 4 ready for prime time?. *Annals of Clinical Biochemistry*, **2014**, 51, 128-36	2.2	13
161	The importance of individual biology in the clinical use of serum biomarkers for ovarian cancer. *Clinical Chemistry and Laboratory Medicine*, **2014**, 52, 1625-31	5.9	19
160	Better blood collection tubes for plasma glucose: ready for prime time?. *Clinical Chemistry and Laboratory Medicine*, **2014**, 52, e87-9	5.9	7
159	Verification of in vitro medical diagnostics (IVD) metrological traceability: responsibilities and strategies. *Clinica Chimica Acta*, **2014**, 432, 55-61	6.2	49
158	Harmonization of automated hemolysis index assessment and use: Is it possible?. *Clinica Chimica Acta*, **2014**, 432, 38-43	6.2	74
157	Biological variation of neuroendocrine tumor markers chromogranin A and neuron-specific enolase. *Clinical Biochemistry*, **2013**, 46, 148-51	3.5	35
156	Standardization and analytical goals for glycated hemoglobin measurement. *Clinical Chemistry and Laboratory Medicine*, **2013**, 51, 1719-26	5.9	19

155	Biologial variation of free light chains in serum. *Clinica Chimica Acta*, **2013**, 415, 10-1	6.2	15
154	Biologic variation of copper, ceruloplasmin and copper/ceruloplasmin ratio (Cu:Cp) in serum. *Clinica Chimica Acta*, **2013**, 415, 295-6	6.2	8
153	Serum albumin: accuracy and clinical use. *Clinica Chimica Acta*, **2013**, 419, 15-8	6.2	40
152	Estimate of intraindividual variability of C-reactive protein: a challenging issue. *Clinica Chimica Acta*, **2013**, 419, 85-6	6.2	7
151	Multi-marker network in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: when and what to measure. *Clinica Chimica Acta*, **2013**, 417, 1-7	6.2	2
150	New insights in the pathophysiology of acute myocardial infarction detectable by a contemporary troponin assay. *Clinical Biochemistry*, **2013**, 46, 999-1006	3.5	5
149	Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review. *Journal of Clinical Pathology*, **2013**, 66, 273-81	3.9	112
148	Measurement of icteric index as approach to detect abnormal total bilirubin values. *Journal of Clinical Pathology*, **2013**, 66, 1095-7	3.9	9
147	Gaps in the traceability chain of human growth hormone measurements. *Clinical Chemistry*, **2013**, 59, 1074-82	5.5	17
146	The Asian project for collaborative derivation of reference intervals: (1) strategy and major results of standardized analytes. *Clinical Chemistry and Laboratory Medicine*, **2013**, 51, 1429-42	5.9	45
145	Measurement imprecision of common urinary biochemical analytes on the Roche Cobas 6000 system. *Clinical Chemistry and Laboratory Medicine*, **2013**, 51, e175-7	5.9	1
144	Standardization and analytical goals for glycated hemoglobin measurement. *Clinical Chemistry and Laboratory Medicine*, **2013**, 51,	5.9	13
143	Defining acceptable limits for the metrological traceability of specific measurands. *Clinical Chemistry and Laboratory Medicine*, **2013**, 51, 973-9	5.9	27
142	Cardiac troponin: a critical review of the case for point-of-care testing in the ED. *American Journal of Emergency Medicine*, **2012**, 30, 1639-49	2.9	66
141	Commutability of two JCTLM-listed secondary reference materials for two commercial lithium assays. *Clinica Chimica Acta*, **2012**, 414, 152-3	6.2	4
140	Comparative study of a new quantitative rapid test with an established ELISA method for faecal calprotectin. *Clinica Chimica Acta*, **2012**, 413, 350-1	6.2	16
139	Hemoglobin, bilirubin, and lipid interference on Roche Cobas 6000 assays. *Clinica Chimica Acta*, **2012**, 413, 339-41; author reply 342-3	6.2	11
138	Inside ST-elevation myocardial infarction by monitoring concentrations of cardiovascular risk biomarkers in blood. *Clinica Chimica Acta*, **2012**, 413, 888-93	6.2	13

137	Biologic variability of C-reactive protein: is the available information reliable?. *Clinica Chimica Acta*, **2012**, 413, 1179-83	6.2	28
136	Diagnostic value of transferrin. *Clinica Chimica Acta*, **2012**, 413, 1184-9	6.2	51
135	Soluble transferrin receptor (sTfR) and sTfR/log ferritin index for the diagnosis of iron-deficiency anemia. A meta-analysis. *American Journal of Clinical Pathology*, **2012**, 138, 642-9	1.9	72
134	The prognostic value of plasma fibrinogen concentrations of patients with ST-elevation myocardial infarction and treated by primary percutaneous coronary intervention: a cautionary message. *Scandinavian Journal of Clinical and Laboratory Investigation*, **2012**, 72, 355-62	2	3
133	Implementation of new recommendations for the diagnosis of gestational diabetes: a 5-month audit. *Clinical Chemistry and Laboratory Medicine*, **2012**, 50, 1271-3	5.9	1
132	Fatal electrolyte abnormalities following enema administration. *Clinical Chemistry*, **2012**, 58, 1515-8	5.5	7
131	Revaluating serum ferritin as a marker of body iron stores in the traceability era. *Clinical Chemistry and Laboratory Medicine*, **2012**, 50, 1911-6	5.9	31
130	Implementation of standardization in clinical practice: not always an easy task. *Clinical Chemistry and Laboratory Medicine*, **2012**, 50, 1237-41	5.9	54
129	Enzyme and Rate Analyses **2012**, 355-377		1
128	Serum Enzymes **2012**, 565-598		4
127	IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 °C. Part 9: reference procedure for the measurement of catalytic concentration of alkaline phosphatase International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Scientific Division, Committee on Reference Systems of Enzymes (C-RSE) (1)). *Clinical Chemistry and*	5.9	57
126	Is the accuracy of serum albumin measurements suitable for clinical application of the test?. *Clinica Chimica Acta*, **2011**, 412, 791-2	6.2	20
125	Revaluation of biological variation of glycated hemoglobin (HbA(1c)) using an accurately designed protocol and an assay traceable to the IFCC reference system. *Clinica Chimica Acta*, **2011**, 412, 1412-6	6.2	42
124	Target organ damage in a population at intermediate cardiovascular risk, with adjunctive major risk factors: CArdiovascular PREvention Sacco Study (CAPRESS). *Internal and Emergency Medicine*, **2011**, 6, 337-47	3.7	1
123	The analytical goals for hemoglobin A(1c) measurement in IFCC units and National Glycohemoglobin Standardization Program Units are different. *Clinical Chemistry*, **2011**, 57, 1204-6	5.5	67
122	Focusing on the clinical impact of standardization of creatinine measurements: a report by the EFCC Working Group on Creatinine Standardization. *Clinical Chemistry and Laboratory Medicine*, **2011**, 49, 977-82	5.9	33
121	Commutability of the ERM-DA470k reference material for two assays measuring serum albumin using immunochemical principles. *Clinical Chemistry and Laboratory Medicine*, **2011**, 49, 1383-1384	5.9	7
120	Impact of implementation of the high-sensitivity cardiac troponin T assay in a university hospital setting. *Clinical Chemistry*, **2011**, 57, 1211-2	5.5	8

119	Obtaining reference intervals traceable to reference measurement systems: is it possible, who is responsible, what is the strategy?. *Clinical Chemistry and Laboratory Medicine*, **2011**, 50, 813-7	5.9	27
118	Traceability of values for catalytic activity concentration of enzymes: a Certified Reference Material for aspartate transaminase. *Clinical Chemistry and Laboratory Medicine*, **2010**, 48, 795-803	5.9	3
117	Development of a candidate secondary reference procedure (immunoassay based measurement procedure of higher metrological order) for cardiac troponin I: I. Antibody characterization and preliminary validation. *Clinical Chemistry and Laboratory Medicine*, **2010**, 48, 1603-10	5.9	11
116	Application of traceability concepts to analytical quality control may reconcile total error with uncertainty of measurement. *Clinical Chemistry and Laboratory Medicine*, **2010**, 48, 7-10	5.9	55
115	Standardization in clinical enzymology: a challenge for the theory of metrological traceability. *Clinical Chemistry and Laboratory Medicine*, **2010**, 48, 301-7	5.9	23
114	Imprecision of tumour biomarker measurements on Roche Modular E170 platform fulfills desirable goals derived from biological variation. *Annals of Clinical Biochemistry*, **2010**, 47, 171-3	2.2	9
113	Common reference intervals for aspartate aminotransferase (AST), alanine aminotransferase (ALT) and Eglutamyl transferase (GGT) in serum: results from an IFCC multicenter study. *Clinical Chemistry and Laboratory Medicine*, **2010**, 48, 1593-601	5.9	63
112	Biological variability of glycated hemoglobin. *Clinica Chimica Acta*, **2010**, 411, 1606-10	6.2	42
111	Standardisation of cardiac troponin I measurement: past and present. *Pathology*, **2010**, 42, 402-8	1.6	60
110	Cardiac: is this biomarker ready for the prime time?. *Scandinavian Journal of Clinical and Laboratory Investigation*, **2010**, 242, 66-72	2	4
109	Standardization of ceruloplasmin measurements is still an issue despite the availability of a common reference material. *Analytical and Bioanalytical Chemistry*, **2010**, 397, 521-5	4.4	15
108	Reference intervals: the way forward. *Annals of Clinical Biochemistry*, **2009**, 46, 8-17	2.2	118
107	A critical appraisal of experimental factors influencing the definition of the 99th percentile limit for cardiac troponins. *Clinical Chemistry and Laboratory Medicine*, **2009**, 47, 1179-82	5.9	20
106	Traceability as a unique tool to improve standardization in laboratory medicine. *Clinical Biochemistry*, **2009**, 42, 236-40	3.5	66
105	Assay-related issues in the measurement of cardiac troponins. *Clinica Chimica Acta*, **2009**, 402, 88-93	6.2	58
104	Enzymatic assays for creatinine: time for action. *Scandinavian Journal of Clinical and Laboratory Investigation*, **2008**, 241, 84-8	2	35
103	Trueness verification of actual creatinine assays in the European market demonstrates a disappointing variability that needs substantial improvement. An international study in the framework of the EC4 creatinine standardization working group. *Clinical Chemistry and Laboratory Medicine*, **2008**, 46, 1319-25	5.9	40
102	Final considerations. *Scandinavian Journal of Clinical and Laboratory Investigation*, **2008**, 241, 109	2	

101	Enzymatic assays for creatinine: time for action. *Clinical Chemistry and Laboratory Medicine*, **2008**, 46, 567-72	5.9	68
100	What's in a name? Standardisation of HbA(1c): a response. *Clinical Chemistry and Laboratory Medicine*, **2008**, 46, 1326-7	5.9	4
99	Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use. *American Journal of Clinical Pathology*, **2008**, 130, 688-95	1.9	137
98	Standardization of troponin I measurements: an update. *Clinical Chemistry and Laboratory Medicine*, **2008**, 46, 1501-6	5.9	40
97	Reference intervals for serum creatinine concentrations: assessment of available data for global application. *Clinical Chemistry*, **2008**, 54, 559-66	5.5	159
96	Markers of Kidney Disease: 11th Bergmeyer Conference, IFCC-Roche Diagnostics Master Discussion, Improving the Clinical Value of Laboratory Data. Foreword. *Scandinavian Journal of Clinical and Laboratory Investigation*, **2008**, 241, 5	2	
95	National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biomarkers of heart failure. *Clinical Biochemistry*, **2008**, 41, 222-6	3.5	19
94	Prevalence of pancreatic insufficiency in inflammatory bowel diseases. Assessment by fecal elastase-1. *Digestive Diseases and Sciences*, **2008**, 53, 262-70	4	37
93	National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biochemical markers of acute coronary syndromes. *Clinical Chemistry*, **2007**, 53, 547-51	5.5	168
92	Serum folate concentrations in patients with cortical and subcortical dementias. *Neuroscience Letters*, **2007**, 420, 213-6	3.3	7
91	National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine practice guidelines: Analytical issues for biomarkers of heart failure. *Circulation*, **2007**, 116, e95-8	16.7	68
90	Traceability, reference systems and result comparability. *Clinical Biochemist Reviews*, **2007**, 28, 97-104	7.3	55
89	Traceability in clinical enzymology. *Clinical Biochemist Reviews*, **2007**, 28, 155-61	7.3	11
88	Toward standardization of cardiac troponin I measurements part II: assessing commutability of candidate reference materials and harmonization of cardiac troponin I assays. *Clinical Chemistry*, **2006**, 52, 1685-92	5.5	76
87	10% CV concentration for the fourth generation Roche cardiac troponin T assay derived from Internal Quality Control data. *Clinical Chemistry and Laboratory Medicine*, **2006**, 44, 1495-6	5.9	14
86	Pretreatment of serum with penicillamine: effects on capillary electrophoresis patterns and on immunonephelometric measurement of immunoglobulins. *Clinical Chemistry*, **2006**, 52, 772-4	5.5	1
85	Cardiac Natriuretic Hormones as Markers of Cardiovascular Disease: Methodological Aspects **2006**, 65-89		4
84	The importance of analytical quality specifications for biomarker assays currently used in acute cardiac care. *Acute Cardiac Care*, **2006**, 8, 133-8		5

83	Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. *Clinical Chemistry*, **2006**, 52, 5-18	5.5	912
82	The importance of metrological traceability on the validity of creatinine measurement as an index of renal function. *Clinical Chemistry and Laboratory Medicine*, **2006**, 44, 1287-92	5.9	35
81	Trueness verification and traceability assessment of results from commercial systems for measurement of six enzyme activities in serum: an international study in the EC4 framework of the Calibration 2000 project. *Clinica Chimica Acta*, **2006**, 368, 160-7	6.2	32
80	The new definition of myocardial infarction and the impact of troponin determination on clinical practice. *International Journal of Cardiology*, **2006**, 106, 298-306	3.2	30
79	Redefining reference limits needs more attention to the analytical aspects. *Liver International*, **2006** , 26, 1155-6	7.9	3
78	Selection of antibodies and epitopes for cardiac troponin immunoassays: should we revise our evidence-based beliefs?. *Clinical Chemistry*, **2005**, 51, 803-4	5.5	24
77	National survey on the use of measurement of cholinesterase activity in serum. *Clinical Chemistry and Laboratory Medicine*, **2005**, 43, 256-7	5.9	
76	Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. *Clinical Chemistry*, **2005**, 51, 810-24	5.5	340
75	Quality specifications for B-type natriuretic peptide assays. *Clinical Chemistry*, **2005**, 51, 486-93	5.5	161
74	Standardization of cardiac troponin I measurements: the way forward?. *Clinical Chemistry*, **2005**, 51, 1594-7	5.5	33
73	Measurement of troponin I 48 h after admission as a tool to rule out impaired left ventricular function in patients with a first myocardial infarction. *Clinical Chemistry and Laboratory Medicine*, **2005**, 43, 848-54	5.9	12
72	Innotrac aio! Second-generation cardiac troponin I assay: imprecision profile and other key characteristics for clinical use. *Clinical Chemistry*, **2004**, 50, 1271-2	5.5	13
71	The interfering component in cardiac troponin I immunoassays: need for further experimental evidence. *Clinical Chemistry*, **2004**, 50, 676-7	5.5	6
70	Multicenter evaluation of the TOSOH AIA-pack second-generation cardiac troponin I assay. *Clinical Chemistry*, **2004**, 50, 1707-9	5.5	8
69	AACC creatine kinase MB (CK-MB) standardization material used as manufacturer's working calibrator is unable to harmonize CK-MB results between two commercial immunoassays. *Clinical Chemistry*, **2004**, 50, 1711-2	5.5	9
68	Current concepts in standardization of cardiac marker immunoassays. *Clinical Chemistry and Laboratory Medicine*, **2004**, 42, 3-8	5.9	14
67	External quality assessment for biochemical markers of myocardial damage: an Italian experience. *Clinical Chemistry and Laboratory Medicine*, **2004**, 42, 1434-41	5.9	5
66	Evaluation of imprecision for cardiac troponin assays at low-range concentrations. *Clinical Chemistry*, **2004**, 50, 327-32	5.5	306

65	Multicenter evaluation of analytical performance of the Liaison troponin I assay. *Clinical Biochemistry*, **2004**, 37, 750-7	3.5	13
64	Role and importance of biochemical markers in clinical cardiology. *European Heart Journal*, **2004**, 25, 1187-96	9.5	98
63	Standardization of immunoassays for measurement of myoglobin in serum. Phase I: evaluation of candidate secondary reference materials. *Clinica Chimica Acta*, **2004**, 341, 65-72	6.2	18
62	The future of laboratory medicine: understanding the new pressures. *Clinical Biochemist Reviews*, **2004**, 25, 207-15	7.3	36
61	Biochemical markers of cardiac diseases. *Journal of Medical Biochemistry*, **2004**, 23, 201-211		4
60	Frequency of butyrylcholinesterase gene mutations in individuals with abnormal inhibition numbers: an Italian-population study. *Pharmacogenetics and Genomics*, **2003**, 13, 265-70		34
59	Assay using succinyldithiocholine as substrate: the method of choice for the measurement of cholinesterase catalytic activity in serum to diagnose succinyldicholine sensitivity. *Clinical Chemistry and Laboratory Medicine*, **2003**, 41, 317-22	5.9	7
58	Rapid determination of brain natriuretic peptide in patients with acute myocardial infarction. *Clinical Chemistry and Laboratory Medicine*, **2003**, 41, 164-8	5.9	17
57	On the comparison of serum and plasma samples in troponin assays. *Clinical Chemistry*, **2003**, 49, 835-6	5.5	4
56	Reference interval for lactate dehydrogenase catalytic activity in serum measured according to the new IFCC recommendations. *Clinical Chemistry and Laboratory Medicine*, **2003**, 41, 970-1	5.9	10
55	Recommendations on Use of Biochemical Markers in Acute Coronary Syndrome: IFCC Proposals. *Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine*, **2003** , 14, 104-108	2.4	1
54	Standardization of Cardiac Markers **2003**, 213-229		1
53	IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. Part 2. Reference procedure for the measurement of catalytic concentration of creatine kinase. *Clinical Chemistry and Laboratory Medicine*, **2002**, 40, 635-42	5.9	71
52	IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. International Federation of Clinical Chemistry and Laboratory Medicine. Part 6. Reference procedure for the measurement of catalytic concentration of	5.9	76
51	IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. International Federation of Clinical Chemistry and Laboratory Medicine. Part 5. Reference procedure for the measurement of catalytic concentration of aspartate	5.9	120
50	IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. International Federation of Clinical Chemistry and Laboratory Medicine. Part 4. Reference procedure for the measurement of catalytic concentration of alanine	5.9	130
49	IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. Part 3. Reference procedure for the measurement of catalytic concentration of lactate dehydrogenase. *Clinical Chemistry and Laboratory Medicine*, **2002**, 40, 643-8	5.9	56
48	Recommendations for the routine use of pancreatic amylase measurement instead of total amylase for the diagnosis and monitoring of pancreatic pathology. *Clinical Chemistry and Laboratory Medicine*, **2002**, 40, 97-100	5.9	17

47	The measurement of cardiac markers: where should we focus?. *American Journal of Clinical Pathology*, **2002**, 118, 354-61	1.9	29
46	Acute coronary syndrome: biochemical strategies in the troponin era. *Chest*, **2002**, 122, 1428-35	5.3	50
45	IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. International Federation of Clinical Chemistry and Laboratory Medicine. Part 7. Certification of four reference materials for the determination of enzymatic activity of gamma-glutamyltransferase, lactate dehydrogenase, alanine aminotransferase and creatine kinase	5.9	35
44	Evaluation of a sandwich enzyme-linked immunosorbent assay for the measurement of serum heart fatty acid-binding protein. *Annals of Clinical Biochemistry*, **2002**, 39, 404-5	2.2	21
43	IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. Part 1. The concept of reference procedures for the measurement of catalytic activity concentrations of enzymes. *Clinical Chemistry and Laboratory Medicine*, **2002**, 40, 631-4	5.9	31
42	Single-Point Cardiac Troponin T at Coronary Care Unit Discharge after Myocardial Infarction Correlates with Infarct Size and Ejection Fraction. *Clinical Chemistry*, **2002**, 48, 1432-1436	5.5	79
41	Performance of Today's Cardiac Troponin Assays and Tomorrow's. *Clinical Chemistry*, **2002**, 48, 809-810	5.5	36
40	Single-point cardiac troponin T at coronary care unit discharge after myocardial infarction correlates with infarct size and ejection fraction. *Clinical Chemistry*, **2002**, 48, 1432-6	5.5	23
39	Comparative study of cardiac troponin I and T measurements in a routine extra-cardiological clinical setting. *Journal of Clinical Laboratory Analysis*, **2001**, 15, 210-4	3	7
38	Establishing a reference system in clinical enzymology. *Clinical Chemistry and Laboratory Medicine*, **2001**, 39, 795-800	5.9	37
37	Evaluation of a rapid bedside immunochromatographic assay for detection of cardiac troponin I in whole blood. *Clinical Chemistry and Laboratory Medicine*, **2001**, 39, 458-9	5.9	6
36	Certification of the mass concentration of creatine kinase isoenzyme 2 (CK-MB) in the reference material BCR 608. *Clinical Chemistry and Laboratory Medicine*, **2001**, 39, 858-65	5.9	5
35	Recent approaches in standardization of cardiac markers. *Clinica Chimica Acta*, **2001**, 311, 19-25	6.2	16
34	Standardization of Cardiac Troponin I Assays: Round Robin of Ten Candidate Reference Materials. *Clinical Chemistry*, **2001**, 47, 431-437	5.5	102
33	Biological Variation in Serum Activities of Three Hepatic Enzymes. *Clinical Chemistry*, **2001**, 47, 355-356	5.5	10
32	Present issues in the determination of troponins and other markers of cardiac damage. *Clinical Biochemistry*, **2000**, 33, 161-6	3.5	28
31	Multicenter Evaluation of Five Assays for Myoglobin Determination. *Clinical Chemistry*, **2000**, 46, 1631-1637	5.5	18
30	Serum and Plasma Samples for ACS:Systems Cardiac Markers. *Clinical Chemistry*, **2000**, 46, 1020-1022	5.5	15

29	Biological Variation in Serum Type I Collagen Carboxy-Terminal Telopeptide Concentrations. *Clinical Chemistry*, **2000**, 46, 1439-1440	5.5	1
28	Evaluation of a fully automated assay to measure C-telopeptide of type I collagen in serum. *Clinical Chemistry and Laboratory Medicine*, **2000**, 38, 1111-3	5.9	15
27	Determination of decision limits for ACS:systems cardiac troponin I. *Clinical Chemistry and Laboratory Medicine*, **2000**, 38, 1155-7	5.9	8
26	The sensitivity of cardiac markers: an evidence-based approach. *Clinical Chemistry and Laboratory Medicine*, **1999**, 37, 1097-106	5.9	52
25	Use of biochemical markers in acute coronary syndromes. IFCC Scientific Division, Committee on Standardization of Markers of Cardiac Damage. International Federation of Clinical Chemistry. *Clinical Chemistry and Laboratory Medicine*, **1999**, 37, 687-93	5.9	82
24	Cardiac troponin elevations in chronic renal failure: prevalence and clinical significance. *Clinical Biochemistry*, **1999**, 32, 125-30	3.5	69
23	Clinical and analytical performance of automated immunochemiluminometric assays for determination of cardiac markers in serum. *Luminescence*, **1998**, 13, 307-9		6
22	Diagnostic application of CK-MB mass determination. *Clinica Chimica Acta*, **1998**, 272, 23-31	6.2	24
21	IFCC Committee on Standardization of Markers of Cardiac Damage: premises and project presentation. International Federation of Clinical Chemistry and Laboratory Medicine. *Clinical Chemistry and Laboratory Medicine*, **1998**, 36, 887-93	5.9	15
20	Myosin Light and Heavy Chains **1998**, 245-256		
19	Biological Variation of Myoglobin in Serum. *Clinical Chemistry*, **1997**, 43, 2435-2435	5.5	40
18	Rapid, Highly Sensitive Immunoassay for Determination of Cardiac Troponin I in Patients with Myocardial Cell Damage. *Clinical Chemistry*, **1997**, 43, 1464-1465	5.5	21
17	Enzyme and muscle diseases. *Current Opinion in Rheumatology*, **1995**, 7, 469-74	5.3	14
16	Nonenzymic glycation of apolipoprotein B in patients with insulin- and noninsulin-dependent diabetes mellitus. *Clinical Biochemistry*, **1995**, 28, 587-92	3.5	6
15	Significance of various parameters derived from biological variability for lipid and lipoprotein analyses. *Clinical Biochemistry*, **1993**, 26, 415-20	3.5	10
14	Diagnostic value of four assays for lipase determination in serum: a comparative reevaluation. *Clinical Biochemistry*, **1991**, 24, 497-503	3.5	7
13	An immunochemical procedure for determination of creatine kinase 3(1) (serum-specific) isoform in human serum evaluated. *Clinical Biochemistry*, **1990**, 23, 225-8	3.5	6
12	Diagnostic value of measuring pancreatic isoamylase with a double-monoclonal antibody immunoassay in serum of hospitalized hyperamylasemic patients. *Journal of Clinical Laboratory Analysis*, **1990**, 4, 449-52	3	8

11	Aspartate aminotransferase isoenzymes. *Clinical Biochemistry*, **1990**, 23, 311-9	3.5	61
10	Time course of changes in serum activity of the P3 isoform of pancreatic amylase isoenzyme in patients with acute pancreatitis. *Clinical Biochemistry*, **1989**, 22, 479-82	3.5	4
9	Methods for serum cholinesterase assay and classification of genetic variants. *Clinica Chimica Acta*, **1989**, 183, 87-90	6.2	4
8	Serum isoforms of creatine kinase isoenzymes. *Clinical Biochemistry*, **1988**, 21, 211-8	3.5	36
7	Serum isoforms of creatine kinase MM and MB in myocardial infarction. An appraisal of quantitative, clinical and pathophysiological information. *Scandinavian Journal of Clinical and Laboratory Investigation*, **1987**, 47, 325-329	2	11
6	Evaluation of a new method for cholinesterase determination. *Clinical Biochemistry*, **1986**, 19, 161-5	3.5	8
5	Serum enzymes in acute myocardial infarction after intracoronary thrombolysis. *Clinical Biochemistry*, **1986**, 19, 294-7	3.5	14
4	Evaluation of the direct potentiometric method for serum chloride determination--comparison with the most commonly employed methodologies. *Clinical Biochemistry*, **1986**, 19, 20-5	3.5	8
3	Isoforms of creatine kinase MM and MB in acute myocardial infarction: a clinical evaluation. *Clinica Chimica Acta*, **1986**, 155, 1-9	6.2	27
2	A simple method for quantitative determination of lipoprotein-X (LP-X) in human serum. *Clinica Chimica Acta*, **1985**, 151, 187-92	6.2	2
1	A single reagent method for determination of total and conjugated bilirubin with a centrifugal analyser. *Clinica Chimica Acta*, **1983**, 128, 407-14	6.2	0